ANN ARBOR, Mich., April 19, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced an agreement with Currax Pharmaceuticals LLC that provides for all of Currax’s 72 sales representatives to co-promote NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets. This deal more than doubles the sales representatives…Read More
Esperion Announces CoPromotion Agreement With Currax Pharmaceuticals LLC
